WELCOME TO The PHARMACEUTICAL REPORT
Pharma Consulting Group (PCG)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Veeva Systems | October 07, 2021
Veeva Systems (NYSE: VEEV ) announced that Celerion has launched Veeva eConsent , a MyVeeva for Patients solution, to provide electronic consent for its Phase I clinical trials obtain. With Veeva eConsent, Celerion is moving from manual and paper-based consent forms to a fully digital process. The company uses Veeva eConsent for several studies and has already given their consent to more than 200 test subjects.
Covid-19 limited the time we cou...
LabRoots | January 20, 2020
Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...
IQVIA™ | September 14, 2021
IQVIA™ , a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmac...
Pfizer | August 17, 2021
Pfizer Inc. and BioNTech SE today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies’ COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks.
“The data we’ve seen to date suggest a third dose of our vaccine elicits antibody levels...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE